GenXys Health Care Systems recently finalized another customer deal to advance precision medicine initiatives.
Vancouver-based GenXys, a global leader in precision prescribing software with embedded pharmacogenetic data, will work with Ohio-based Flexsus, the laboratory division of FlexHealth.
“The GenXys software suite will allow Flexsus to offer unparalleled services to its customers and improve patient safety and treatment response,” explains Samuel Tang, CEO of Flexsus. “The flexibility of the GenXys platform coupled with the company’s unwavering focus on established evidence made them a clear fit for our providers and patients who want the ultimate confidence in the prescribing decisions.”
Combined with GenXys’ precision prescribing platform, Flexsus can now perform pharmacogenomic testing and report results that identify medication that may be most efficacious for individuals based upon their genomic profile, with the goal of enhancing patient wellness.
“As North America’s powerhouse support tool for precision prescribing, we are proud of the number of pharmacogenomic profiles our software processes,” said Karl Pringle, CEO of GenXys. “Being a cloud-based solution means all our customers are conforming to the latest clinical and pharmacogenetic guidelines set by CPIC, FDA, and other industry groups.”
GenXys’ software will ensure differentiated pharmacogenomic solutions for the Flexsus networked pharmacists and expanded medication review capabilities. GenXys will overlay its expertise with the delivery of a seamless connection and securitized data flow between Laboratory Information Management Systems, electronic health records, and other systems.
“Providing evidence-based prescribing support with real-time pharmacogenomic assessment and inclusion is becoming a must-have, not a nice-to-have,” Pringle said. “Through the integration with Flexsus, we’re also able to include existing medication history into the clinical decision support process and enable providers to use data automatically at the point of care.”
Last year the Canadian company landed a similar deal with Precision Genetics.